{
    "organizations": [],
    "uuid": "ab19731e005a399ace48286decfbe878b2429d66",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sangui-biotech-revenues-of-54000-i/brief-sangui-biotech-revenues-of-54000-in-h1-idUSASM000IAN",
    "ord_in_thread": 0,
    "title": "BRIEF-Sangui Biotech: Revenues Of $54,000 In H1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - SANGUI BIOTECH INTERNATIONAL INC :\n* DGAP-NEWS: SANGUI BIOTECH INTERNATIONAL INC.: - REVENUES OF USD 54,000 IN THE FIRST HALF-YEAR; GRANULOX LICENSE INCOME INCREASED BY 54%.\n* REVENUES OF USD 54,000 IN FIRST HALF-YEAR; Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-19T17:32:00.000+02:00",
    "crawled": "2018-01-20T17:38:03.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "sangui",
        "biotech",
        "international",
        "inc",
        "sangui",
        "biotech",
        "international",
        "revenue",
        "usd",
        "first",
        "granulox",
        "license",
        "income",
        "increased",
        "revenue",
        "usd",
        "first",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}